Please select the option that best describes you:

In locally advanced EGFR-mutated NSCLC with initial good response to osimertinib, how do you manage local progression of the primary?   

Would you consider SBRT and continue osimertinib?



Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more